Latest Zelboraf Stories

Researchers from UCLA's Jonsson Comprehensive Cancer Center, together with scientists from 12 other sites in the United States and Australia, report for the first time that a newly approved drug for patients with metastatic melanoma nearly doubles median survival times, a finding that will change the way this deadly form of skin cancer is treated. The data comes from an international Phase II study of Zelboraf that included 132 patients followed for at least one year. Patients with this...

The US Food and Drug Administration (FDA) on Wednesday approved the cancer treatment drug Zelboraf, used to treat patients with late-stage or unresectable melanoma, the most dangerous form of skin cancer. The drug specifically treats patients with melanoma whose tumors express a gene mutation called BRAF V600E. The drug has not been tested on patients whose melanoma tests negative for the mutation by an approved FDA diagnostic. Zelboraf is being approved with a test called the cobas 4800 BRAF...